Why is Spyre Therapeutics, Inc. stock down today?
August 7, 2026
Spyre Therapeutics, Inc.
SYRE · NMS · USD
vs. prev. close $104.35
Last updated Aug 6, 2026 20:00
Intraday Chart — 5-min intervals
SYRE · less than a minute ago
Spyre Therapeutics, Inc. dips 0.89% — Motley Fool reports
Spyre Therapeutics, Inc. (SYRE) is trading lower, at $103. 42 — down 0. 89% from yesterday's close of $104. 35. Today's move appears driven by recent headlines, including "Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know" and "A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know".
News sentiment around SYRE is leaning mixed. The broader market is under pressure (S&P 500: -0. 2%, Nasdaq: -0. 1%, Dow Jones: -0. 9%, Shanghai: +1. 3%, Hang Seng: +0. 3%). Past performance does not guarantee future results.
Key Factors
Auto-generated analysis · Not financial advice
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
Motley Fool·about 7 hours agoneutralA Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
Motley Fool·about 7 hours agoneutralSpyre Therapeutics Insider Sold Shares Worth $1,432,705, According to a Recent SEC Filing
MT Newswires·about 23 hours agoneutralSYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Zacks·1 day agoneutralWedbush Adjusts Price Target on Spyre Therapeutics to $130 From $100, Maintains Outperform Rating
MT Newswires·2 days agoneutralSpyre Therapeutics: Q2 Earnings Snapshot
Associated Press·2 days agoneutralSpyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire·2 days agoneutralMizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating
MT Newswires·25 days agoneutral
S&P 500
-0.18%
Nasdaq
-0.06%
Dow Jones
-0.85%
Shanghai
+1.34%
Hang Seng
+0.31%
Nikkei 225
-0.21%
FTSE 100
-0.19%
Nifty 50
-0.33%
DAX
+0.05%
OMX Stockholm
-0.12%
Search another stock